Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer

To explore how DOCK1 deficiency enhances the anti-tumor effects of metformin, we performed RNA-seq analysis in PLC cells expressing NTC or shDOCK1 in the presence or absence of metformin. RNA-seq analysis in PLC cells expressing NTC or shDOCK1 in the presence or absence of metformin.